Increased alveolar nitric oxide concentration and high levels of leukotriene B4 and 8-isoprostane in exhaled breath condensate in patients with asbestosis

Thorax

Volumn 62, Issue 7, 2007, Pages 602-607

  Lehtonen, Hannele ^a   Oksa, Panu ^a   Lehtimäki, Lauri ^a,b   Sepponen, Anna ^a   Nieminen, Riina ^a   Kankaanranta, Hannu ^a,b   Saarelainen, Seppo ^b   Järvenpää, Ritva ^b   Uitti, Jukka ^a   Moilanen, Eeva ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTANE; C REACTIVE PROTEIN; INTERLEUKIN 6; LEUKOTRIENE B4; MYELOPEROXIDASE; NITRIC OXIDE;

ADULT; AGED; ARTICLE; ASBESTOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; INFLAMMATION; LUNG FIBROSIS; LUNG PARENCHYMA; MALE; PRIORITY JOURNAL;

AGED; ASBESTOSIS; BREATH TESTS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DINOPROST; HUMANS; INTERLEUKIN-6; LEUKOTRIENE B4; MALE; MIDDLE AGED; NITRIC OXIDE; PEROXIDASE; PULMONARY ALVEOLI; RESPIRATORY FUNCTION TESTS;

EID: 34447303533     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2006.067868     Document Type: Article

References (52)

1. Manning CB, Vallyathan V, Mossman BT. Diseases caused by asbestos: mechanisms of injury and disease development. Int Immunopharmacol 2002;2:191-200.
2. Ross MH, Murray J. Occupational respiratory disease in mining. Occup Med 2004;54:304-10.
3. Bolton C, Richards A, Ebden P. Asbestos-related disease. Hosp Med 2002;63:148-51.
4. American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2004;170:691-715.
5. Ross RM. The clinical diagnosis of asbestosis in this century requires more than a chest radiograph. Chest 2003;124:1120-8.
6. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001;163:1693-722.
7. American Thoracic Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912-30.
8. Vallance P, Leiper J. Blocking NO synthesis: how, where and why? Nature Reviews, Drug Discovery 2002;1:939-50.
9. Ricciardolo FL. Multiple roles of nitric oxide in the airways. Thorax 2003;58:175-82.
10. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001;357:593-615.
11. Korhonen R, Lahti A, Kankaanranta H, et al. Nitric oxide production and signaling in inflammation. Curr Drug Targets-Inflamm Allergy 2005;4:471-9.
12. Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1993;6:1368-70.
13. Kharitonov SA, Yates D, Robbins RA, et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994;343:133-5.
14. Lehtimäki L, Kankaanranta H, Soarelainen S, et al. Extended exhaled NO measurement differentiates between alveolar and bronchial inflammation. Am J Respir Crit Care Med 2001;163:1557-61.
15. Maziak W, Loukides S, Culpitt S, et al. Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:998-1002.
16. Paredi P, Kharitonov SA, Loukides S, et al. Exhaled nitric oxide is increased in active fibrosing alveolitis. Chest 1999;115:1352-6.
17. Tsoukias NM, George SC. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol 1998;85:653-66.
18. George SC, Högman M, Permuff S, et al. Modeling pulmonary nitric oxide exchange. J Appl Physiol 2004;96:831-9.
19. Silkoff PE, Sylvester JT, Zamel N, et al. Airway nitric oxide diffusion in asthma: role in pulmonary function and bronchial responsiveness. Am J Respir Crit Care Med 2000;161:1218-28.
20. Lehtimäki L. Measurement of exhaled nitric oxide. Acta Univ Tamperensis 2003:925.
21. Lehtimäki L, Turjanmaa V, Kankaanranta H, et al. Increased bronchial nitric oxide production in patients with asthma measured with a novel method of different exhalation flow rates. Ann Med 2000;32:417-23.
22. Shin HW, Rose-Gottron CM, Cooper DM, et al. Airway diffusing capacity of nitric oxide and steroid therapy in asthma. J Appl Physiol 2004;96:65-75.
23. Deldaux C, Mahut B, Zerah-Lancner F, et al. Increased nitric oxide output from alveolar origin during liver cirrhosis versus bronchial source during asthma. Am J Respir Crit Care Med 2002;165:332-7.
24. Högman M, Holmkvist T, Wegener T, et al. Extended NO analysis applied to patients with COPD, allergic asthma and allergic rhinitis. Respir Med 2002;96:24-30.
25. Brindicci C, Ito K, Resta O, et al. Exhaled nitric oxide from lung periphery is increased in COPD. Eur Respir J 2005;26:52-9.
26. Horvath I, Hunt J, Barnes PJ, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005;26:523-48.
27. Anon. Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health 1997;23:311-6.
28. Oksa P, Suoranta H, Koskinen H, et al. High-resolution computed tomography in the early detection of asbestosis. Int Arch Occup Environ Health 1994;65:299-304.
29. Huuskonen O, Kivisaari L, Zitting A, et al. High-resolution computed tomography classification of lung fibrosis for patients with asbestos-related disease. Scand J Work Environ Health 2001;27:106-12.
30. Hyde RW, Geigel EJ, Olszowka AJ, et al. Determination of production of nitric oxide by lower airways of humans-theory. J Appl Physiol 1997;82:1290-6.
31. Borland CD, Higenbottam TW. A simultaneous single breath measurement of pulmonary diffusing capacity with nitric oxide and carbon monoxide. Eur Respir J 1989;2:56-63.
32. Viljanen AA, Viljanen BC, Halttunen PK, et al. Pulmonary diffusing capacity and volumes in healthy adults measured with the single breath technique. Scand J Clin Lab Invest 1982;159:21-34.
33. Lehtimäki L, Kankaanranta H, Saarelainen S, et al. Inhaled fluticasone decreases bronchial but not alveolar nitric oxide output in asthma. Eur Respir J 2001;18:635-9.
34. Girgis RE, Gugnani MK, Abrams J, et al. Partitioning of alveolar and conducting airway nitric oxide in scleroderma lung disease. Am J Respir Crit Care Med 2002;165:1587-91.
35. Lehtimäki L, Kankaanranta H, Saarelainen S, et al. Increased alveolar nitric oxide concentration in asthmatic patients with nocturnal symptoms. Eur Respir J 2002;20:841-5.
36. Lehtimäki L, Kankaanranta H, Saarelainen S, et al. Peripheral inflammation in patients with asthmatic symptoms but normal lung function. J Asthma 2005;42:605-9.
37. Mahut B, Deldaux C, Tillie-Leblond I, et al. Both inflammation and remodeling influence nitric oxide output in children with refractory asthma. J Allergy Clin Immunol 2004;113:252-6.
38. Begin R, Cantin A, Berthiaume Y, et al. Clinical features to stage alveolitis in asbestos workers. Am J Ind Med 1985;8:521-36.
39. Saleh D, Barnes PJ, Giaid A. Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997;155:1763-9.
40. Park SH, Aust AE. Regulation of nitric oxide synthase induction by iron and glutathione in asbestos-treated human lung epithelial cells. Arch Biochem Biophys 1998;360:47-52.
41. Dorger M, Allmeling AM, Kiefmann R, et al. Dual role of inducible nitric oxide synthase in acute asbestos-induced lung injury. Free Radic Biol Med 2002;33:491-501.
42. Dorger M, Allmeling AM, Kiefmann R, et al. Early inflammatory response to asbestos exposure in rat and hamster lungs: role of inducible nitric oxide synthase. Toxicol Appl Pharm 2002;181:93- 105.
43. Sandrini A, Johnson AR, Thomas PS, et al. Fractional exhaled nitric oxide concentration is increased in asbestosis and pleural plaques. Respirology 2006;11:325-9.
44. Garcia JG, Griffith DE, Cohen AB, et al. Alveolar macrophages from patients with asbestos exposure release increased levels of leukotriene B4. Am Rev Respir Dis 1989;139:1494-501.
45. Montuschi P, Kharitonov SA, Ciabattoni G, et al. Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003;58:585-8.
46. Cap P, Chladek J, Pehal F, et al. Gas chromatography/mass spectrometry analysis of exhaled leukotrienes in asthmatic patients. Thorax 2004;59:465-70.
47. Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003;58:294-8.
48. Baraldi E, Ghiro L, Piovan V, et al. Increased exhaled 8-isoprostane in childhood asthma. Chest 2003;124:25-31.
49. Montuschi P, Kharitonov SA, Ciabattoni G, et al. Exhaled 8-isoprostane as a new non-invasive biomarker of oxidative stress in cystic fibrosis. Thorax 2000;55:205-9.
50. Carpenter CT, Price PV, Christman BW. Exhaled breath condensate isoprostanes are elevated in patients with acute lung injury or ARDS. Chest 1998;114:1653-9.
51. Begin R, Cantin A, Drapeau G, et al. Pulmonary uptake of gallium-67 in asbestos-exposed humans and sheep. Am Rev Respir Dis 1983;127:623-30.
52. Oksa P, Huuskonen MS, Jarvisalo J, et al. Follow-up of asbestosis patients and predictors for radiographic progression. Int Arch Occup Environ Health 1998;71:465-71.